Company Performance Metrics
Founded in 2012, Montisera is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its own and partners’ product platform in a broad range of disease areas. Montisera utilises novel drug development strategy emphasising the power of cooperation between drug development companies, biotechnology
companies, academy, individual scientists and investors. In August 2014 Montisera announced a patent which covers the use of novel 6,7-disubstituted-isoquinoline derivatives as a medicament and particularly in the treatment of alcoholism, drug addiction and CNS related diseases. Montisera announces that also the European Patent Office (EPO) intends to grant a patent for the novel 6,7-disubstituted-isoquinoline derivatives and medical use thereof. In May 2015 Montisera acquired the IPR's for an extract having effect on lower urinary tract diseases.
